Zura Bio Ltd shareholders approved Binding Organizational Documents Proposal B: A proposal to change the post-Business Combination corporate name from "JATT Acquisition Corp" to "Zura Bio Limited," to make the post-Business Combination company's corporate existence perpetual and to eliminate provisions specific to its status as a bla at the 2023-03-16 meeting.
“Binding Organizational Documents Proposal B: A proposal to change the post-Business Combination corporate name from "JATT Acquisition Corp" to "Zura Bio Limited," to make the post-Business Combination company's corporate existence perpetual and to eliminate provisions specific to its status as a blank check company . The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”
Shareholder Votes
Zura Bio Ltd shareholders approved Binding Organizational Documents Proposal A: A proposal to approve the change in authorized share capital of the Company to $30,100 divided into 300,000,000 Class A ordinary shares, no Class B ordinary shares, and 1,000,000 preference shares. at the 2023-03-16 meeting.
“Binding Organizational Documents Proposal A: A proposal to approve the change in authorized share capital of the Company to $30,100 divided into 300,000,000 Class A ordinary shares, no Class B ordinary shares, and 1,000,000 preference shares. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”
Shareholder Votes
Zura Bio Ltd shareholders approved A proposal to approve and adopt the Business Combination Agreement. at the 2023-03-16 meeting.
“The Business Combination Proposal A proposal to approve and adopt the Business Combination Agreement. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”
Material Agreements
Zura Bio Ltd amended Amendment No. 2 to Forward Purchase Agreement with Athanor Master Fund, LP and Athanor International Master Fund, LP valued at up to $15,000,000 (effective 2023-03-08).
“On March 8, 2023, JATT Acquisition Corp (the “Company” or “JATT”), Athanor Master Fund, LP, and Athanor International Master Fund, LP (collectively, the “Purchasers”) entered into Amendment No. 2 to Forward Purchase Agreement and Related Agreements, pursuant to which, among other things, the Purchasers agreed to purchase up to 1,500,000 shares of JATT’s Class A ordinary shares (“Class A Shares”) from the Company for an aggregate purchase price of up to $15,000,000 in the event that redemptions exceed certain thresholds.”
Material Agreements
Zura Bio Ltd amended Third Amendment to the BCA with JATT Acquisition Corp, JATT Merger Sub, JATT Merger Sub 2, Zura Bio Holdings Ltd, Zura Bio Limited (effective 2023-01-16).
“on January 16, 2023, JATT, Merger Sub, Merger Sub 2, Zura and Holdco entered into the third amendment to the Original Business Combination Agreement (the “ Third Amendment to the BCA ”) to extend the Outside Date to April 17, 2023.”
Material Agreements
Zura Bio Ltd entered into Equity Grant Agreement with Eli Lilly and Company valued at JATT to issue and grant to Lilly 550,000 Class A ordinary shares in a private placement transaction (effective 2022-12-08).
“Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that certain Equity Grant Agreement, pursuant to which JATT agreed to issue and grant to Lilly 550,000 Class A ordinary shares of JATT (the “ Shares ”) in a private placement transaction.”
Material Agreements
Zura Bio Ltd entered into License, Development and Commercialization Agreement with Eli Lilly and Company valued at License granted regarding intellectual property rights for a certain compound relating to IL-33 (effective 2022-12-08).
“Effective on December 8, 2022, Z33 Bio Inc. (“ Z33 ”), an entity controlled by Zura entered into the License, Development and Commercialization Agreement (the “ License Agreement ”) with Eli Lilly and Company (“ Lilly ”), pursuant to which Lilly granted a license to Z33 regarding certain intellectual property rights for a certain compound relating to IL-33 to develop, manufacture and commercialize such compound, subject to the terms and conditions set forth therein.”
Josh Distler resigned as director at Zura Bio Ltd.
“On September 24, 2021, JATT Acquisition Corp (the “Company”) received a letter of resignation from Josh Distler pursuant to which Mr. Distler resigned as a director of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.